Search

Xencor Inc

Ouvert

SecteurSoins de santé

29.8 2.69

Résumé

Variation du prix de l'action

24h

Actuel

Min

28.16

Max

31.79

Chiffres clés

By Trading Economics

Revenu

107M

-22M

Ventes

47M

51M

BPA

-0.29

Marge bénéficiaire

-42.422

Employés

260

EBITDA

109M

-12M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+16.86% upside

Dividendes

By Acuity

Prochains Résultats

3 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

286M

1.7B

Ouverture précédente

27.11

Clôture précédente

29.8

Xencor Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

26 oct. 2026, 23:06 UTC

Xencor Inc shares are trading modestly higher in after-market hours, remaining significantly above their 20-day moving average amid improved economic activity signals.

23 oct. 2026, 20:02 UTC

Xencor Inc shares fell sharply, reaching a significant low mid-morning before a slight rebound, continuing a downward trend since Thursday.

22 oct. 2026, 20:07 UTC

Xencor Inc shares advanced, finishing stronger and marking the fifth consecutive day of gains, despite some retracement earlier in the session.

21 oct. 2026, 21:01 UTC

Xencor Inc is advancing in after-market trading, reaching its highest cumulative return of the day and significantly above its 20-day moving average.

20 oct. 2026, 20:02 UTC

Event

Xencor Inc will host a webcast on October 26 to discuss Phase 1 Study results of XmAb819 for advanced clear cell renal cell carcinoma.

19 oct. 2026, 20:07 UTC

News
Event
Social Media

Xencor Inc will host a webcast on October 26 to discuss Phase 1 study results of XmAb819 ahead of the ESMO Congress presentation.

16 oct. 2026, 20:07 UTC

Correlated Moves

Xencor Inc shares are declining amid a broader downturn in the biotechnology sector, with the SPDR S&P Biotech ETF (XBI) also lower due to negative analyst commentary.

15 oct. 2026, 19:26 UTC

Correlated Moves

Xencor Inc shares are advancing, supported by gains in the SPDR S&P Biotech ETF following analyst upgrades and positive news from Recursion Pharmaceuticals.

14 oct. 2026, 22:26 UTC

Xencor Inc shares are trading modestly lower in after-market hours, continuing a downward trend and currently about 5.70% below their 20-day moving average.

13 oct. 2026, 20:01 UTC

Xencor Inc shares fell sharply, diverging from recent higher daily closes, amid unusually high trading volume today.

9 oct. 2026, 20:06 UTC

Correlated Moves

Xencor Inc shares are higher, reflecting broader market gains, as the SPDR S&P Biotech ETF rises on news of Moderna's cancer vaccine partnership.

8 oct. 2026, 20:07 UTC

Xencor Inc shares are modestly higher as the broader market recovers from an earlier low, showing a cumulative return of nearly 0.93%.

6 oct. 2026, 20:02 UTC

Correlated Moves

Xencor Inc shares fell sharply, influenced by the declining SPDR S&P Biotech ETF amid concerns over inflation risks and dilution from public offerings.

2 oct. 2026, 19:55 UTC

Xencor Inc shares fell, continuing a four-session decline, after peaking early in the day amid broader weakness in the biotechnology sector.

30 sept. 2026, 20:07 UTC

News

Shares of Xencor Inc. fell sharply despite Wells Fargo initiating coverage with an Overweight rating and a $55.00 price target.

29 sept. 2026, 19:46 UTC

Xencor Inc shares fell sharply, showing unusual volatility and dipping nearly 4% since Monday's close before recovering slightly.

28 sept. 2026, 20:02 UTC

News

Truist Securities raised its price target on Xencor Inc to $29.00, as the stock experiences unusually high volume and continues to gain sharply.

24 sept. 2026, 19:46 UTC

Xencor Inc shares fell sharply, continuing a downward trend since Wednesday and remaining significantly below its 20-day moving average amid broader market weakness.

23 sept. 2026, 20:07 UTC

Correlated Moves

Xencor Inc shares fell sharply, reflecting a broader decline linked to significant losses in the Direxion Daily S&P Biotech Bull 3X ETF.

22 sept. 2026, 19:45 UTC

Xencor Inc is modestly higher, continuing positive momentum after four consecutive sessions of gains, despite remaining below its 20-day moving average.

21 sept. 2026, 20:31 UTC

Xencor Inc. has risen in after-market trading, recovering from an initial dip and reaching a peak notably higher than Monday's close.

17 sept. 2026, 20:07 UTC

Correlated Moves

Xencor Inc is advancing, likely supported by a rally in the biotechnology sector following positive Phase 3 results for Moderna's cancer vaccine.

16 sept. 2026, 19:16 UTC

Xencor Inc is trading roughly flat, having fluctuated within a typical range but remains significantly below its 20-day moving average.

15 sept. 2026, 23:16 UTC

Shares of Xencor Inc. are lower in after-market hours amid broader market pressures and rising yields on the ten-year Treasury note.

10 sept. 2026, 20:07 UTC

Xencor Inc's shares are lower today, continuing a trend of three consecutive daily declines and trading below the 20-day moving average.

8 sept. 2026, 20:07 UTC

Xencor Inc shares are trading lower today, following a notable early decline and remaining below their 20-day moving average. No specific news was identified.

4 sept. 2026, 20:07 UTC

Xencor Inc shares are higher, recovering from earlier losses amid broader market selling pressure following a strong jobs report. No specific news was identified.

3 sept. 2026, 22:15 UTC

News

Shares lower in after-market trading after JP Morgan's rating.

2 sept. 2026, 20:08 UTC

Xencor Inc shares are lower today, reversing from an early gain amid a weaker-than-expected ADP employment report affecting investor sentiment on interest rates.

1 sept. 2026, 23:01 UTC

Xencor Inc shares are lower in after-market hours, with no specific news identified. This decline occurs amid broader market concerns over economic growth data.

Comparaison

Variation de prix

Xencor Inc prévision

Objectif de Prix

By TipRanks

16.86% hausse

Prévisions sur 12 Mois

Moyen 34.1 USD  16.86%

Haut 46 USD

Bas 20 USD

Basé sur 13 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

13 ratings

11

Achat

2

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.
help-icon Live chat